WO2022038475 - PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE
National phase entry:
Publication Number
WO/2022/038475
Publication Date
24.02.2022
International Application No.
PCT/IB2021/057474
International Filing Date
13.08.2021
Title **
[English]
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE
[French]
COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT DE LA MALADIE DE PARKINSON
Applicants **
PIKE THERAPEUTICS, INC.
20th Floor
250 Howe Street
Vancouver, British Columbia V6C 3R8, CA
Inventors
PLAKOGIANNIS, Fotios M.
157-14 Cryders Lane
Whitestone, New York 11357, US
MODI, Nisarg
32 Logan Ave.
1st Floor
Jersey City, New Jersey 07306, US
Priority Data
63/066,386
17.08.2020
US
63/229,021
03.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2756 | |
| EPO | Filing, Examination | 22996 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 9710 |
Total: 36656 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The current application relates to a topical pharmaceutical composition comprising at least one active agent selected from CBD and THC, solvent, surfactant, optional permeation enhancer, and optional adhesive/polymer. The topical composition is used for treating, preventing, or slowing the onset or progression of Parkinson's disease and/or related symptoms.[French]
La présente demande concerne une composition pharmaceutique topique comprenant au moins un agent actif choisi parmi le CBD et le THC, un solvant, un tensioactif, un activateur de perméation facultatif, ainsi qu'un adhésif/polymère facultatif. La composition topique est utilisée pour traiter, prévenir ou ralentir l'apparition ou la progression de la maladie de Parkinson et/ou des symptômes associés.